{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:34:18Z","timestamp":1790508858751,"version":"4.1.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"5-6","license":[{"start":{"date-parts":[[2008,5,14]],"date-time":"2008-05-14T00:00:00Z","timestamp":1210723200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycopathologia"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1007\/s11046-008-9109-0","type":"journal-article","created":{"date-parts":[[2008,5,13]],"date-time":"2008-05-13T12:54:03Z","timestamp":1210683243000},"page":"353-367","source":"Crossref","is-referenced-by-count":251,"title":["Update in Antifungal Therapy of Dermatophytosis"],"prefix":"10.1007","volume":"166","author":[{"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,5,14]]},"reference":[{"key":"9109_CR1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.yadr.2006.07.001","volume":"22","author":"DS Loo","year":"2006","unstructured":"Loo DS. Systemic antifungal agents: an update of established and new therapies. Adv Dermatol. 2006;22:101\u201324.","journal-title":"Adv Dermatol"},{"issue":"Suppl 1","key":"9109_CR2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1468-3083.2005.01284.x","volume":"19","author":"M Lecha","year":"2005","unstructured":"Lecha M, Effendy I, Feuilhade de Chauvin M, Di Chiacchio N, Baran R. Treatment options\u2014development of consensus guidelines. J Eur Acad Dermatol Venereol. 2005;19(Suppl 1):25\u201333.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"9109_CR3","unstructured":"TARO Pharmaceuticals Inc. Clotrimazole cream USP, 1%. Prescribing information. Bramalea, Ontario, Canada, June 1996."},{"key":"9109_CR4","unstructured":"TARO Pharmaceuticals Inc. Econazole nitrate cream 1%. Prescribing information. Brampton, Ontario, Canada, September 2001."},{"key":"9109_CR5","unstructured":"Merz Pharmaceuticals. Naftin\u00ae Naftifine HCl 1% gel\/cream. Prescribing information. Greensboro, NC, USA, May 2007."},{"key":"9109_CR6","unstructured":"McNeil Consumer & Specialty Pharmaceuticals. Nizoral\u00ae (ketoconazole) 2% shampoo. Prescribing information. Fort Washington, PA, USA, October 2003."},{"key":"9109_CR7","unstructured":"TARO Pharmaceuticals Inc. Ciclopirox olamine cream USP, 0.77%. Prescribing information. Brampton, Ontario, Canada, March 2005."},{"key":"9109_CR8","unstructured":"MEDICIS, The Dermatology Company. Loprox\u00ae Gel (ciclopirox) 0.77%. Prescribing information. Scottsdale, AZ, USA, July 2005."},{"key":"9109_CR9","unstructured":"BERTEK Pharmaceuticals Inc. Mentax\u00ae-TC (butenafine HCl) cream, 1%. Prescribing information. Research Triangle Park, NC, USA, October 2002."},{"key":"9109_CR10","unstructured":"GlaxoSmithKline Consumer Healthcare LP. Oxistat\u00ae (oxiconazole nitrate cream) cream 1%; Oxistat\u00ae (oxiconazole nitrate lotion) lotion 1%. Prescribing information. Pittsburgh, PA, USA, January 2004."},{"key":"9109_CR11","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0733-8635(03)00032-9","volume":"21","author":"AK Gupta","year":"2003","unstructured":"Gupta AK, Chow M, Daniel CR, Aly R. Treatments of tinea pedis. Dermatol Clin. 2003;21:431\u201362.","journal-title":"Dermatol Clin"},{"key":"9109_CR12","unstructured":"Lamisil\u00ae (terbinafine hydrochloride tablets) Prescribing information. Novartis Pharmaceuticals Corporation. East Hanover, NJ, November 2005."},{"key":"9109_CR13","unstructured":"Sporanox\u00ae (itraconazole) Capsules prescribing information (Ortho-McNeil Inc). Janssen Pharmaceutica Products, L.P. Titusville, NJ, June 2006."},{"key":"9109_CR14","unstructured":"Diflucan\u00ae (fluconazole tablets) (fluconazole injection\u2014for intravenous infusion only) (fluconazole for oral suspension) Prescribing information. Pfizer Inc, August 2004."},{"key":"9109_CR15","unstructured":"Griseofulvin (Systemic). In: Drug information for the health care professional, USP DI, The United States Pharmacopeial Convention, Inc., ed 24, Taunton MA, 2004, Micromedex, p. 1493\u20136."},{"key":"9109_CR16","unstructured":"Miscellaneous Antifungals\u2014Griseofulvin. In: AHFS Drug Information\u00ae 2005. Bethesda, MD, 2005, American Society of Health-System Pharmacists, Inc., p. 535\u20137."},{"key":"9109_CR17","unstructured":"Azoles\u2014Ketoconazole. In: AHFS Drug Information\u00ae 2005. Bethesda, MD, 2005, American Society of Health-System Pharmacists, Inc., p. 510\u20136."},{"key":"9109_CR18","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0733-8635(03)00033-0","volume":"21","author":"AK Gupta","year":"2003","unstructured":"Gupta AK, Cooper EA, Montero-Gei F. The use of fluconazole to treat superficial fungal infections in children. Dermatol Clin. 2003;21:537\u201342.","journal-title":"Dermatol Clin"},{"key":"9109_CR19","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0733-8635(03)00030-5","volume":"21","author":"AK Gupta","year":"2003","unstructured":"Gupta AK, Cooper EA, Ginter G. Efficacy and safety of itraconazole use in children. Dermatol Clin. 2003;21:521\u201335.","journal-title":"Dermatol Clin"},{"key":"9109_CR20","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0733-8635(03)00029-9","volume":"21","author":"AK Gupta","year":"2003","unstructured":"Gupta AK, Cooper EA, Lynde CW. The efficacy and safety of terbinafine in children. Dermatol Clin. 2003;21:511\u201320.","journal-title":"Dermatol Clin"},{"key":"9109_CR21","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0733-8635(03)00027-5","volume":"21","author":"AK Gupta","year":"2003","unstructured":"Gupta AK, Ryder JE. The use of oral antifungal agents to treat onychomycosis. Dermatol Clin. 2003;21:469\u201379.","journal-title":"Dermatol Clin"},{"key":"9109_CR22","unstructured":"Antifungals, Azole (Systemic). In: Drug information for the health care professional, USP DI, The United States Pharmacopeial Convention, Inc., ed 24, Taunton MA, 2004, Micromedex. p. 315\u201323."},{"key":"9109_CR23","first-page":"215","volume-title":"Topley and Wilson\u2019s medical mycology","author":"AA Padhye","year":"1998","unstructured":"Padhye AA, Weitzman I. The dermatophytes. In: Collier L, Balows A, Sussman M, Ajello L, Hay RJ, editors. Topley and Wilson\u2019s medical mycology. New York: Oxford University Press; 1998. p. 215\u201336."},{"key":"9109_CR24","first-page":"163","volume":"58","author":"SL Noble","year":"1998","unstructured":"Noble SL, Forbes RC, Stamm PL. Diagnosis and management of common tinea infections. Am Fam Physician. 1998;58:163\u20138.","journal-title":"Am Fam Physician"},{"key":"9109_CR25","doi-asserted-by":"crossref","unstructured":"Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD001434.","DOI":"10.1002\/14651858.CD001434.pub2"},{"key":"9109_CR26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00128071-200405040-00003","volume":"5","author":"AK Gupta","year":"2004","unstructured":"Gupta AK, Cooper EA, Ryder JE, et\u00a0al. Optimal management of fungal infections of the skin, hair, and nails. Am J Clin Dermatol. 2004;5:225\u201337.","journal-title":"Am J Clin Dermatol"},{"key":"9109_CR27","first-page":"436","volume-title":"Evidence based dermatology","author":"F Crawford","year":"2003","unstructured":"Crawford F. Athlete\u2019s foot. In: Williams H, Bigby M, Diepgen T, Herxheimer A, Naldi L, Rzany B, editors. Evidence based dermatology. London: BMJ Books; 2003. p. 436\u201340."},{"key":"9109_CR28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0733-8635(03)00031-7","volume":"21","author":"AK Gupta","year":"2003","unstructured":"Gupta AK, Chaudhry M, Elewski B. Tinea corporis, tinea cruris, tinea nigra, and piedra. Dermatol Clin. 2003;21:395\u2013400.","journal-title":"Dermatol Clin"},{"key":"9109_CR29","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0190-9622(97)80351-9","volume":"36","author":"AK Gupta","year":"1997","unstructured":"Gupta AK, De Doncker P, Heremans A, et\u00a0al. Itraconazole for the treatment of tinea pedis: a dose of 400\u00a0mg\/day given for 1\u00a0week is similar in efficacy to 100 or 200\u00a0mg\/day given for 2 to 4\u00a0weeks. J Am Acad Dermatol. 1997;36:789\u201392.","journal-title":"J Am Acad Dermatol"},{"key":"9109_CR30","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2133.1997.tb02144.x","volume":"136","author":"J Faergemann","year":"1997","unstructured":"Faergemann J, Mork NJ, Haglund A, et\u00a0al. A multicentre (double-blind) comparative study to assess the safety and efficacy of fluconazole and griseofulvin in the treatment of tinea corporis and tinea cruris. Br J Dermatol. 1997;136:575\u20137.","journal-title":"Br J Dermatol"},{"key":"9109_CR31","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000017881","volume":"196","author":"A Stary","year":"1998","unstructured":"Stary A, Sarnow E. Fluconazole in the treatment of tinea corporis and tinea cruris. Dermatology. 1998;196:237\u201341.","journal-title":"Dermatology"},{"key":"9109_CR32","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2230.1992.tb00246.x","volume":"17","author":"P Suchil","year":"1992","unstructured":"Suchil P, Montero Gei F, Robles M, et\u00a0al. Once-weekly oral doses of fluconazole 150\u00a0mg in the treatment of tinea corporis\/cruris and cutaneous candidiasis. Clin Exp Dermatol. 1992;17:397\u2013401.","journal-title":"Clin Exp Dermatol"},{"key":"9109_CR33","first-page":"417","volume":"13","author":"TS Haroon","year":"1997","unstructured":"Haroon TS, Asghar HA, Aman S, et\u00a0al. An open, non-comparative study for the evaluation of oral fluconazole in the treatment of tinea corporis. Specialist. 1997;13:417\u201323.","journal-title":"Specialist"},{"key":"9109_CR34","first-page":"77","volume":"7","author":"M Papini","year":"1997","unstructured":"Papini M, Difonzo EM, Cilli P, et\u00a0al. Itraconazole versus fluconazole, a double-blind comparison in tinea corporis. J Mycol M\u00e9d. 1997;7:77\u201380.","journal-title":"J Mycol M\u00e9d"},{"key":"9109_CR35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00044011-199612020-00001","volume":"12","author":"A Kotogyan","year":"1996","unstructured":"Kotogyan A, Harmanyeri Y, Tahsin Gunes A, et\u00a0al. Efficacy and safety of oral fluconazole in the treatment of patients with tinea corporis, cruris or pedis or cutaneous candidiasis. A multicentre, open, non-comparative study. Clin Drug Investig. 1996;12:59\u201366.","journal-title":"Clin Drug Investig"},{"key":"9109_CR36","first-page":"251","volume":"40","author":"M Gomez","year":"1996","unstructured":"Gomez M, Arenas R, Salazar JJ, et\u00a0al. Tinea pedis. A multicentre trial to evaluate the efficacy and tolerance of a weekly dose of fluconazole. Dermatol Rev Mex. 1996;40:251\u20135 (Spanish).","journal-title":"Dermatol Rev Mex"},{"key":"9109_CR37","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1365-2230.1992.tb00247.x","volume":"17","author":"R Aguila Del","year":"1992","unstructured":"Del Aguila R, Montero Gei F, Robles M, et\u00a0al. Once-weekly oral doses of fluconazole 150\u00a0mg in the treatment of tinea pedis. Clin Exp Dermatol. 1992;17:402\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"9109_CR38","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1540-9740.2005.03435.x","volume":"4","author":"AK Gupta","year":"2005","unstructured":"Gupta AK, Ryder JE, Chow M, Cooper EA. Dermatophytosis: the management of fungal infections. Skinmed. 2005;4:305\u201310.","journal-title":"Skinmed"},{"key":"9109_CR39","first-page":"28","volume":"47","author":"JT Trent","year":"2001","unstructured":"Trent JT, Federman D, Kirsner RS. Common viral and fungal skin infections. Ostomy Wound Manage. 2001;47:28\u201334.","journal-title":"Ostomy Wound Manage"},{"key":"9109_CR40","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0190-9622(97)70074-4","volume":"37","author":"P Doncker De","year":"1997","unstructured":"De Doncker P, Gupta AK, Marynissen G, et\u00a0al. Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J Am Acad Dermatol. 1997;37:969\u201374.","journal-title":"J Am Acad Dermatol"},{"key":"9109_CR41","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1159\/000246883","volume":"189","author":"D Parent","year":"1994","unstructured":"Parent D, Decroix J, Heenen M. Clinical experience with short schedules of itraconazole in the treatment of tinea corporis and\/or tinea cruris. Dermatology. 1994;189:378\u201381.","journal-title":"Dermatology"},{"key":"9109_CR42","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/mmy.38.4.255.287","volume":"38","author":"AK Gupta","year":"2000","unstructured":"Gupta AK, Summerbell RC. Tinea capitis. Med Mycol. 2000;38:255\u201387.","journal-title":"Med Mycol"},{"key":"9109_CR43","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3928\/0090-4481-20050301-08","volume":"34","author":"BJ Roberts","year":"2005","unstructured":"Roberts BJ, Friedlander SF. Tinea capitis: a treatment update. Pediatr Ann. 2005;34:191\u2013200.","journal-title":"Pediatr Ann"},{"key":"9109_CR44","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1046\/j.1365-2133.2002.04744.x","volume":"146","author":"J Lipozencic","year":"2002","unstructured":"Lipozencic J, Skerlev M, Orofino-Costa R, et\u00a0al. A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species. Br J Dermatol. 2002;146:816\u201323.","journal-title":"Br J Dermatol"},{"key":"9109_CR45","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.0736-8046.2004.21117.x","volume":"21","author":"AK Gupta","year":"2004","unstructured":"Gupta AK, Skinner AR. Onychomycosis in children: a brief overview with treatment strategies. Pediatr Dermatol. 2004;21:74\u20139.","journal-title":"Pediatr Dermatol"},{"key":"9109_CR46","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0733-8635(03)00034-2","volume":"21","author":"A Tosti","year":"2003","unstructured":"Tosti A, Piraccini BM, Iorizzo M. Management of onychomycosis in children. Dermatol Clin. 2003;21:507\u20139.","journal-title":"Dermatol Clin"},{"key":"9109_CR47","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00001432-200404000-00005","volume":"17","author":"Y Chan","year":"2004","unstructured":"Chan Y, Friedlander SF. New treatments for tinea capitis. Curr Opin Infect Dis. 2004;17:97\u2013103.","journal-title":"Curr Opin Infect Dis"},{"key":"9109_CR48","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1365-2133.1996.tb03613.x","volume":"135","author":"TS Haroon","year":"1996","unstructured":"Haroon TS, Hussain I, Aman S, et\u00a0al. A randomized double-blind comparative study of terbinafine for 1, 2 and 4\u00a0weeks in tinea capitis. Br J Dermatol. 1996;135:86\u20138.","journal-title":"Br J Dermatol"},{"key":"9109_CR49","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1542\/peds.109.4.602","volume":"109","author":"SF Friedlander","year":"2002","unstructured":"Friedlander SF, Aly R, Krafchik B, et\u00a0al. Terbinafine in the treatment of Trichophyton tinea capitis: a randomized, double-blind, parallel-group, duration-finding study. Pediatrics. 2002;109:602\u20137.","journal-title":"Pediatrics"},{"key":"9109_CR50","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1046\/j.1365-2133.2002.04744.x","volume":"146","author":"J Lipozencic","year":"2002","unstructured":"Lipozencic J, Skerlev M, Orofino-Costa R, et\u00a0al. A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species. Br J Dermatol. 2002;146:816\u201323.","journal-title":"Br J Dermatol"},{"key":"9109_CR51","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1046\/j.1365-2133.1998.02323.x","volume":"139","author":"AK Gupta","year":"1998","unstructured":"Gupta AK, Solomon RS, Adam P. Itraconazole oral solution for the treatment of tinea capitis. Br J Dermatol. 1998;139:104\u20136.","journal-title":"Br J Dermatol"},{"key":"9109_CR52","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/09546630510025932","volume":"16","author":"L Dastghaib","year":"2005","unstructured":"Dastghaib L, Azizzadeh M, Jafari P. Therapeutic options for the treatment of tinea capitis: griseofulvin versus fluconazole. J Dermatolog Treat. 2005;16:43\u20136.","journal-title":"J Dermatolog Treat"},{"key":"9109_CR53","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1046\/j.1365-4362.1998.00584.x","volume":"37","author":"F Montero Gei","year":"1998","unstructured":"Montero Gei F. Fluconazole in the treatment of tinea capitis. Int J Dermatol. 1998;37:870\u20131.","journal-title":"Int J Dermatol"},{"key":"9109_CR54","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1046\/j.1365-2133.2000.03479.x","volume":"142","author":"AK Gupta","year":"2000","unstructured":"Gupta AK, Dlova N, Taborda P, et\u00a0al. Once weekly fluconazole is effective in the treatment of tinea capitis: a prospective, multicentre study. Br J Dermatol. 2000;142:965\u20138.","journal-title":"Br J Dermatol"},{"key":"9109_CR55","first-page":"58","volume":"3","author":"AK Gupta","year":"1997","unstructured":"Gupta AK, Scher RK. Management of onychomycosis: a North American perspective. Dermatol Ther. 1997;3:58\u201365.","journal-title":"Dermatol Ther"},{"key":"9109_CR56","first-page":"441","volume-title":"Evidence based dermatology","author":"AK Gupta","year":"2003","unstructured":"Gupta AK, Ryder J, Bluhm R. Onychomycosis. In: Williams H, Bigby M, Diepgen T, Herxheimer A, Naldi L, Rzany B, editors. Evidence based dermatology. London: BMJ Books; 2003. p. 441\u201368."},{"key":"9109_CR57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjopharm.2005.12.012","volume":"4","author":"A Tavakkol","year":"2006","unstructured":"Tavakkol A, Fellman S, Kianifard F. Safety and efficacy of oral terbinafine in the treatment of onychomycosis: analysis of the elderly subgroup in Improving Results in Onychomycosis-Concomitant Lamisil\u00ae and Debridement (IRONCLAD\u00ae), an open-label, randomized trial. Am J Geriatr Pharmacother. 2006;4:1\u201313.","journal-title":"Am J Geriatr Pharmacother"},{"key":"9109_CR58","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/09546630600965004","volume":"18","author":"LP Potter","year":"2007","unstructured":"Potter LP, Mathias SD, Raut M, et\u00a0al. The impact of aggressive debridement used as an adjunct therapy with terbinafine on perceptions of patients undergoing treatment for toenail onychomycosis. J Dermatolog Treat. 2007;18:46\u201352.","journal-title":"J Dermatolog Treat"},{"key":"9109_CR59","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0190-9622(96)90066-3","volume":"35","author":"CR Daniel III","year":"1996","unstructured":"Daniel CR III. Traditional management of onychomycosis. J Am Acad Dermatol. 1996;35:S21\u20135.","journal-title":"J Am Acad Dermatol"},{"key":"9109_CR60","doi-asserted-by":"crossref","first-page":"5","DOI":"10.12968\/jowc.2003.12.1.26455","volume":"12","author":"B King","year":"2003","unstructured":"King B. Pain at first dressing change after toenail avulsion: the experience of nurses, patients and an observer: 1. J Wound Care. 2003;12:5\u201310.","journal-title":"J Wound Care"},{"key":"9109_CR61","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1439-0507.2006.01351.x","volume":"50","author":"C Seebacher","year":"2007","unstructured":"Seebacher C, Brasch D, Abeck O, et\u00a0al. Onychomycosis. Mycoses. 2007;50:321\u20137.","journal-title":"Mycoses"},{"key":"9109_CR62","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1201\/b14710","volume-title":"Review of current antifungal treatment. Onychomycosis: the current approach to diagnosis and therapy","author":"R Baran","year":"1999","unstructured":"Baran R, Hay RJ, Haneke E, Tosti A. Review of current antifungal treatment. Onychomycosis: the current approach to diagnosis and therapy. London: Martin Dunitz Ltd.; 1999. p. 44\u201369."},{"key":"9109_CR63","first-page":"129","volume-title":"Baran and Dawber\u2019s diseases of the nails and their management","author":"RJ Hay","year":"2001","unstructured":"Hay RJ, Baran R, Haneke E. Fungal (onychomycosis) and other infections involving the nail apparatus. In: Baran R, Dawber RPR, de Berker DAR, Haneke E, Tosti A, editors. Baran and Dawber\u2019s diseases of the nails and their management. Osney Mead, Oxford: Blackwell Science Ltd.; 2001. p. 129\u201371."},{"key":"9109_CR64","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2133.2007.08014.x","volume":"157","author":"C Grover","year":"2007","unstructured":"Grover C, Bansal S, Nanda S, et\u00a0al. Combination of surgical avulsion and topical therapy for single nail onychomycosis: a randomized controlled trial. Br J Dermatol. 2007;157:364\u20138.","journal-title":"Br J Dermatol"},{"key":"9109_CR65","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1468-3083.2004.00988.x","volume":"19","author":"R Baran","year":"2005","unstructured":"Baran R, Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol. 2005;19:21\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"9109_CR66","unstructured":"Penlac\u00ae Nail Lacquer (ciclopirox) Topical Solution, 8% Prescribing information. Dermik Laboratories (a division of Sanofi-Aventis). Bridgewater, NJ, July 2006."},{"key":"9109_CR67","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/120347540400800107","volume":"8","author":"AK Gupta","year":"2004","unstructured":"Gupta AK, Ryder JE, Skinner AR. Treatment of onychomycosis: pros and cons of antifungal agents. J Cutan Med Surg. 2004;8:25\u201330.","journal-title":"J Cutan Med Surg"},{"key":"9109_CR68","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jaad.2005.06.019","volume":"53","author":"EM Warshaw","year":"2005","unstructured":"Warshaw EM, St Clair KR. Prevention of onychomycosis reinfection for patients with complete cure of all 10 toenails: results of a double-blind, placebo-controlled, pilot study of prophylactic miconazole powder 2%. J Am Acad Dermatol. 2005;53:717\u201320.","journal-title":"J Am Acad Dermatol"},{"key":"9109_CR69","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1046\/j.1365-4362.1997.00237.x","volume":"36","author":"CR Daniel","year":"1997","unstructured":"Daniel CR, Gupta AK, Daniel MP, Daniel CM. Two feet-one hand syndrome: a retrospective multicenter survey. Int J Dermatol. 1997;36:658\u201360.","journal-title":"Int J Dermatol"},{"key":"9109_CR70","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/09546630500504713","volume":"17","author":"B Sigurgeirsson","year":"2006","unstructured":"Sigurgeirsson B, Elewski BE, Rich PA, et\u00a0al. Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: a randomized, double-blind comparison. J Dermatolog Treat. 2006;17:38\u201344.","journal-title":"J Dermatolog Treat"},{"key":"9109_CR71","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1529-8019.2007.00109.x","volume":"20","author":"JJ Finch","year":"2007","unstructured":"Finch JJ, Warshaw EM. Toenail onychomycosis: current and future treatment options. Dermatol Ther. 2007;20:31\u201346.","journal-title":"Dermatol Ther"},{"issue":"Suppl 65","key":"9109_CR72","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2133.149.s65.2.x","volume":"149","author":"JH Olafsson","year":"2003","unstructured":"Olafsson JH, Sigurgeirsson B, Baran R. Combination therapy for onychomycosis. Br J Dermatol. 2003;149(Suppl 65):15\u20138.","journal-title":"Br J Dermatol"},{"issue":"Suppl 65","key":"9109_CR73","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1365-2133.149.s65.1.x","volume":"149","author":"EGV Evans","year":"2003","unstructured":"Evans EGV. Drug synergies and the potential for combination therapy in onychomycosis. Br J Dermatol. 2003;149(Suppl 65):11\u20133.","journal-title":"Br J Dermatol"},{"key":"9109_CR74","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaad.2004.11.055","volume":"52","author":"MA Nandedkar-Thomas","year":"2005","unstructured":"Nandedkar-Thomas MA, Scher RK. An update on disorders of the nails. J Am Acad Dermatol. 2005;52:877\u201387.","journal-title":"J Am Acad Dermatol"},{"key":"9109_CR75","first-page":"481","volume":"4","author":"AK Gupta","year":"2005","unstructured":"Gupta AK, Onychomycosis Combination Therapy Study Group. Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study. J Drugs Dermatol. 2005;4:481\u20135.","journal-title":"J Drugs Dermatol"},{"issue":"Suppl 60","key":"9109_CR76","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2133.2001.00045.x","volume":"145","author":"R Baran","year":"2001","unstructured":"Baran R. Topical amorolfine for 15\u00a0months combined with 12\u00a0weeks of oral terbinafine, a cost-effective treatment for onychomycosis. Br J Dermatol. 2001;145(Suppl 60):15\u20139.","journal-title":"Br J Dermatol"},{"issue":"Suppl 60","key":"9109_CR77","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-2133.2001.145s60021.x","volume":"145","author":"M Lecha","year":"2001","unstructured":"Lecha M. Amorolfine and itraconazole combination for severe toenail onychomycosis: results of an open randomized trial in Spain. Br J Dermatol. 2001;145(Suppl 60):21\u20136.","journal-title":"Br J Dermatol"},{"key":"9109_CR78","doi-asserted-by":"crossref","first-page":"134","DOI":"10.7547\/0970134","volume":"97","author":"JM Binstock","year":"2007","unstructured":"Binstock JM. Molecular biology techniques for identifying dermatophytes and their possible use in diagnosing onychomycosis in human toenails. J Am Podiatr Med Assoc. 2007;97:134\u201344.","journal-title":"J Am Podiatr Med Assoc"},{"key":"9109_CR79","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ijantimicag.2006.09.028","volume":"29","author":"D Assis Santos de","year":"2007","unstructured":"de Assis Santos D, de Carvalho Araujo RA, Kohler LM, et\u00a0al. Molecular typing and antifungal susceptibility of Trichophyton rubrum isolates from patients with onychomycosis pre- and post-treatment. Int J Antimicrob Agents. 2007;29:563\u20139.","journal-title":"Int J Antimicrob Agents"},{"key":"9109_CR80","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1128\/JCM.02072-06","volume":"45","author":"A Brillowska-Dabrowska","year":"2007","unstructured":"Brillowska-Dabrowska A, Saunte DM, Arendrup MC. Five-hour diagnosis of dermatophyte nail infections with specific detection of Trichophyton rubrum. J Clin Microbiol. 2007;45:1200\u20134.","journal-title":"J Clin Microbiol"},{"key":"9109_CR81","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1128\/JCM.01418-06","volume":"45","author":"C Savin","year":"2007","unstructured":"Savin C, Huck S, Rolland C, et\u00a0al. Multicenter evaluation of a commercial PCR-enzyme-linked immunosorbent assay diagnostic kit (Onychodiag) for diagnosis of dermatophytic onychomycosis. J Clin Microbiol. 2007;45:1205\u201310.","journal-title":"J Clin Microbiol"},{"key":"9109_CR82","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1365-2133.2007.08110.x","volume":"157","author":"AK Gupta","year":"2007","unstructured":"Gupta AK, Zaman M, Singh J. Fast and sensitive detection of Trichophyton rubrum DNA from the nail samples of patients with onychomycosis by a double-round polymerase chain reaction-based assay. Br J Dermatol. 2007;157:698\u2013703.","journal-title":"Br J Dermatol"}],"container-title":["Mycopathologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-008-9109-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11046-008-9109-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-008-9109-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T03:44:14Z","timestamp":1559360654000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11046-008-9109-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,14]]},"references-count":82,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["9109"],"URL":"https:\/\/doi.org\/10.1007\/s11046-008-9109-0","relation":{},"ISSN":["0301-486X","1573-0832"],"issn-type":[{"value":"0301-486X","type":"print"},{"value":"1573-0832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,14]]}}}